.png "United Therapeutics (NASDAQ: UTHR)")
Today, a Director at United Therapeutics (NASDAQ: UTHR), Christopher Causey, sold shares of UTHR for $95.58K.
Following Christopher Causey’s last UTHR Sell transaction on November 27, 2012, the stock climbed by 65.9%. In addition to Christopher Causey, one other UTHR executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
UTHR’s market cap is $5.16B and the company has a P/E ratio of 7.29. Currently, United Therapeutics has an average volume of 203.1K.
Based on 5 analyst ratings, the analyst consensus is Hold with an average price target of $139.50, reflecting a 17.7% upside.
The insider sentiment on United Therapeutics has been negative according to 92 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
Read More on UTHR:
